<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Terapevticheskii arkhiv</journal-id><journal-title-group><journal-title xml:lang="en">Terapevticheskii arkhiv</journal-title><trans-title-group xml:lang="ru"><trans-title>Терапевтический архив</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0040-3660</issn><issn publication-format="electronic">2309-5342</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">626337</article-id><article-id pub-id-type="doi">10.26442/00403660.2023.12.202494</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Molecular mechanisms of the effect of standardized placental hydrolysate peptides on mitochondria functioning</article-title><trans-title-group xml:lang="ru"><trans-title>О молекулярных механизмах воздействия пептидов стандартизированного гидролизата плаценты на функционирование митохондрий</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2659-7998</contrib-id><name-alternatives><name xml:lang="en"><surname>Torshin</surname><given-names>Ivan Yu.</given-names></name><name xml:lang="ru"><surname>Торшин</surname><given-names>Иван Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. физ.-мат. наук, канд. хим. наук, вед. науч. сотр. ФИЦ ИУ РАН</p></bio><email>unesco.gromova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7663-710X</contrib-id><contrib-id contrib-id-type="scopus">7003589812</contrib-id><name-alternatives><name xml:lang="en"><surname>Gromova</surname><given-names>Olga A.</given-names></name><name xml:lang="ru"><surname>Громова</surname><given-names>Ольга Алексеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>д-р мед. наук, проф., вед. науч. сотр. ФИЦ ИУ РАН</p></bio><email>unesco.gromova@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2810-566X</contrib-id><name-alternatives><name xml:lang="en"><surname>Tikhonova</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Тихонова</surname><given-names>Ольга Валентиновна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>канд. биол. наук, рук. Центра коллективного пользования «Протеом человека» ФГБНУ «НИИБМХ им. В.Н. Ореховича»</p></bio><email>unesco.gromova@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6808-5528</contrib-id><name-alternatives><name xml:lang="en"><surname>Chuchalin</surname><given-names>Alexander G.</given-names></name><name xml:lang="ru"><surname>Чучалин</surname><given-names>Александр Григорьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="ru"><p>акад. РАН, д-р мед. наук, проф., зав. каф. госпитальной терапии педиатрического фак-та, председатель правления Российского респираторного общества</p></bio><email>unesco.gromova@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Computer Science and Control</institution></aff><aff><institution xml:lang="ru">ФИЦ «Информатика и управление» Российской академии наук</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Orekhovich Research Institute of Biomedical Chemistry</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт биомедицинской химии им. В.Н. Ореховича»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-12-28" publication-format="electronic"><day>28</day><month>12</month><year>2023</year></pub-date><volume>95</volume><issue>12</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>1133</fpage><lpage>1140</lpage><history><date date-type="received" iso-8601-date="2024-01-31"><day>31</day><month>01</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-01-31"><day>31</day><month>01</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ter-arkhiv.ru/0040-3660/article/view/626337">https://ter-arkhiv.ru/0040-3660/article/view/626337</self-uri><abstract xml:lang="en"><p><bold>Background.</bold> Human placenta hydrolysates (HPH), the study of which was initiated by the scientific school of Vladimir P. Filatov, are currently being investigated using modern proteomic technologies. HPH is a promising tool for maintaining the function of mitochondria and regenerating tissues and organs with a high content of mitochondria (liver, heart muscle, skeletal muscles, etc.). The molecular mechanisms of action of HPH are practically not studied.</p> <p><bold>Aim.</bold> Identification of mitochondrial support mitochondrial function-supporting peptides in HPH (Laennec, produced by Japan Bioproducts).</p> <p><bold>Materials and methods. </bold>Data on the chemical structure of the peptides were collected through a mass spectrometric experiment. Then, to establish the amino acid sequences of the peptides, <italic>de novo</italic> peptide sequencing algorithms based on the mathematical theory of topological and metric analysis of chemographs were applied. Bioinformatic analysis of the peptide composition of HPH was carried out using the integral protein annotation method.</p> <p><bold>Results. </bold>The biological functions of 41 peptides in the composition of HPH have been identified and described. Among the target proteins, the activity of which is regulated by the identified peptides and significantly affects the function of mitochondria, are caspases (CASP1, CASP3, CASP4) and other proteins regulating apoptosis (BCL2, CANPL1, PPARA), MAP kinases (MAPK1, MAPK3, MAPK4, MAPK8, MAPK9 , MAPK10, MAPK14), AKT1/GSK3B/MTOR cascade kinases, and a number of other target proteins (ADGRG6 receptor, inhibitor of NF-êB kinase IKKE, pyruvate dehydrogenase 2/3/4, SIRT1 sirtuin deacetylase, ULK1 kinase).</p> <p><bold>Conclusion. </bold>HPH peptides have been identified that promote inhibition of mitochondrial pore formation, apoptosis, and excessive mitochondrial autophagy under conditions of oxidative/toxic stress, chronic inflammation, and/or hyperinsulinemia.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность. </bold>Гидролизаты плаценты человека (ГПЧ), начало изучения которых было положено научной школой В.П. Филатова, в настоящее время исследуются посредством современных протеомных технологий. ГПЧ представляют собой перспективное средство для поддержания функции митохондрий и регенерации тканей и органов с высоким содержанием митохондрий (печени, сердечной мышцы, скелетной мускулатуры и др.). Молекулярные механизмы действия ГПЧ практически не изучены.</p> <p><bold>Цель. </bold>Идентификация в составе ГПЧ (Лаеннек, Japan Bioproducts) пептидов, поддерживающих функционирование митохондрий.</p> <p><bold>Материалы и методы. </bold>Данные о химической структуре пептидов собирали посредством масс-спектрометрического эксперимента. Затем для установления аминокислотных последовательностей пептидов применены алгоритмы <italic>de novo</italic> секвенирования пептидов, основанные на математической теории топологического и метрического анализа хемографов. Биоинформационный анализ пептидного состава ГПЧ осуществлен посредством интегрального метода аннотации белков.</p> <p><bold>Результаты. </bold>Идентифицированы и описаны биологические функции 41 пептида в составе ГПЧ. Среди таргетных белков, активность которых регулируется выявленными пептидами и существенно влияет на функцию митохондрий, представлены каспазы (CASP1, CASP3, CASP4) и другие белки регуляции апоптоза (BCL2, CANPL1, PPARA), митоген-активируемые протеинкиназы (MAPK1, MAPK3, MAPK4, MAPK8, MAPK9, MAPK10, MAPK14), киназы каскада AKT1/GSK3B/MTOR и ряд других таргетных белков (рецептор ADGRG6, ингибитор киназы IKKE ядерного фактора каппа-би (NF-êB), пируватдегидрогеназы 2/3/4, НАД-зависимая деацетилаза сиртуин SIRT1, киназа ULK1).</p> <p><bold>Заключение. </bold>Установлены пептиды ГПЧ, способствующие торможению формирования митохондриальной поры, апоптоза и избыточной аутофагии митохондрий в условиях оксидативного/токсического стресса, хронического воспаления и/или гиперинсулинемии.</p></trans-abstract><kwd-group xml:lang="en"><kwd>mitochondrial deficiency</kwd><kwd>human placenta hydrolyzate</kwd><kwd>Laennec</kwd><kwd>comorbid conditions</kwd><kwd>bioinformatics</kwd><kwd>topological data analysis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>митохондриальная недостаточность</kwd><kwd>гидролизат плаценты человека</kwd><kwd>Лаеннек</kwd><kwd>коморбидные состояния</kwd><kwd>биоинформатика</kwd><kwd>топологический анализ данных</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This work was supported by a grant from the Russian Science Foundation (project No. 23-21-00154)</funding-statement><funding-statement xml:lang="ru">Работа выполнена по гранту Российского научного фонда (проект №23-21-00154)</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Максимов В.А., Громова О.А., Диброва Е.А. Сборник авторефератов докторских и кандидатских диссертаций по проблеме тканевой терапии плаценты. М.: Модуль, 2022 [Maksimov VA, Gromova OA, Dibrova EA. Sbornik avtoreferatov doktorskikh i kandidatskikh dissertatsii po probleme tkanevoi terapii platsenty. Moscow: Modul', 2022 (in Russian)].</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Громова О.А., Торшин И.Ю., Чучалин А.Г., Максимов В.А. Гидролизаты плаценты человека: от В.П. Филатова до наших дней. Терапевтический архив. 2022;94(3):434-41 Gromova OA, Torshin IYu, Chuchalin AG, Maximov VA. Human placenta hydrolysates: from V.P. Filatov to the present day: Review. Terapevticheskii Arkhiv (Ter. Arkh.). 2022;94(3):434–441 (in Russian)]. DOI:10.26442/00403660.2022.03.201408</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Северин Е.С., Алейникова Т.Л., Осипов Е.В., Силаева С.А. Биологическая химия. М.: Медицинское информационное агентство, 2008 [Severin ES, Aleinikova TL, Osipov EV, Silaeva SA. Biologicheskaia khimiia. Moscow: Meditsinskoe informatsionnoe agentstvo, 2008 (in Russian)].</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>McClintock CR, Mulholland N, Krasnodembskaya AD. Biomarkers of mitochondrial dysfunction in acute respiratory distress syndrome: A systematic review and meta-analysis. Front Med (Lausanne). 2022;9:1011819. DOI:10.3389/fmed.2022.1011819</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Торшин И.Ю., Громова О.А., Назаренко А.Г. Хондропротекторы как модуляторы нейровоспаления. Неврология, нейропсихиатрия, психосоматика. 2023;15(1):110-8 [Torshin IYu, Gromova OA, Nazarenko AG. Chondroprotectors as modulators of neuroinflammation. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(1):110-8 (in Russian)]. DOI:10.14412/2074-2711-2023-1-110-118</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17(3):290-314. DOI:10.1038/mp.2010.136</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Liang L, Chen J, Xiao L, et al. Mitochondrial modulators in the treatment of bipolar depression: A systematic review and meta-analysis. Transl Psychiatry. 2022;12(1):4. DOI:10.1038/s41398-021-01727-7</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Song T, Song X, Zhu C, et al. Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer's disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies. Ageing Res Rev. 2021;72:101503. DOI:10.1016/j.arr.2021.101503</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 7th ed. New York: W.H. Freeman, 2017.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Громова О.А., Торшин И.Ю., Максимов В.А., и др. Пептиды в составе препарата Лаеннек, способствующие устранению гиперферритинемии и перегрузки железом. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(4):413-25 [Gromova OA, Torshin IYu, Maksimov VA, et al. Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):413-25 (in Russian)]. DOI:10.17749/2070-4909/farmakoekonomika.2020.070</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Громова О.А., Торшин И.Ю., Тихонова О.В., Згода В.Г. Гепатопротекторные пептиды препарата Лаеннек. Экспериментальная и клиническая гастроэнтерология. 2022;203(7):21-30 [Torshin IYu, Gromova OA, Tikhonova OV, Zgoda VG. Hepatoprotective peptides of the drug Laennec. Experimental and Clinical Gastroenterology. 2022;(7):21-30 (in Russian)]. DOI:10.31146/1682-8658-ecg-203-7-21-30</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Torshin IYu, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 2: metric approach within the framework of the theory of classification of feature values. Pattern Recognit Image Anal. 2017;27(2):184-99. DOI:10.1134/S1054661817020110</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Torshin IYu, Rudakov KV. On the application of the combinatorial theory of solvability to the analysis of chemographs. Part 1: Fundamentals of modern chemical bonding theory and the concept of the chemograph. Pattern Recognit Image Anal. 2014;24:11-23. DOI:10.1134/S1054661814010209</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Torshin IYu, Rudakov KV. On the procedures of generation of numerical features over partitions of sets of objects in the problem of predicting numerical target variables. Pattern Recognit Image Anal. 2019;29(4):654-67. DOI:10.1134/S1054661819040175</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Torshin IYu, Rudakov KV. Combinatorial analysis of the solvability properties of the problems of recognition and completeness of algorithmic models. Part 1: Factorization approach. Pattern Recognit Image Anal. 2017;27(1):16-28. DOI:10.1134/S1054661817010151</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Torshin IYu. Optimal dictionaries of the final information on the basis of the solvability criterion and their applications in bioinformatics. Pattern Recognit Image Anal. 2013;23(2):319-27. DOI:10.1134/S1054661813020156</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Torshin IYu. Sensing the change from molecular genetics to personalized medicine. New York: Nova Biomedical Books, 2009.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Mirica SN, Duicu OM, Trancota SL, et al. Magnesium orotate elicits acute cardioprotection at reperfusion in isolated and in vivo rat hearts. Can J Physiol Pharmacol. 2013;91(2):108-15. DOI:10.1139/cjpp-2012-0216</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Sileikyte J, Petronilli V, Zulian A, Ricchelli F. Regulation of the inner membrane mitochondrial permeability transition by the outer membrane translocator protein (peripheral benzodiazepine receptor). J Biol Chem. 2011;286(2):1046-53. DOI:10.1074/jbc.M110.172486</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Zhang Y, Dong Y, Xu Z, Xie Z. Propofol and magnesium attenuate isoflurane-induced caspase-3 activation via inhibiting mitochondrial permeability transition pore. Med Gas Res. 2012;2(1):20. DOI:10.1186/2045-9912-2-20</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Jorquera R, Tanguay RM. Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis. FASEB J. 1999;13(15):2284-98. DOI:10.1096/fasebj.13.15.2284</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Shao G, Wang L, Wang X, Fu C. Apaf-1/caspase-4 pyroptosome: A mediator of mitochondrial permeability transition-triggered pyroptosis. Signal Transduct Target Ther. 2021;6(1):116. DOI:10.1038/s41392-021-00524-4</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Blasche S, Mörtl M, Steuber H, et al. The E. coli effector protein NleF is a caspase inhibitor. PLoS One. 2013;8(3):e58937. DOI:10.1371/journal.pone.0058937</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Wen S, Wang L, Zhang W, et al. Induction of mitochondrial apoptosis pathway mediated through caspase-8 and c-Jun N-terminal kinase by cadmium-activated Fas in rat cortical neurons. Metallomics. 2021;13(7):mfab042. DOI:10.1093/mtomcs/mfab042</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Samraj AK, Sohn D, Schulze-Osthoff K, Schmitz I. Loss of caspase-9 reveals its essential role for caspase-2 activation and mitochondrial membrane depolarization. Mol Biol Cell. 2007;18(1):84-93. DOI:10.1091/mbc.e06-04-0263</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Chen M, Guerrero AD, Huang L, et al. Caspase-9-induced mitochondrial disruption through cleavage of anti-apoptotic BCL-2 family members. J Biol Chem. 2007;282(46):33888-95. DOI:10.1074/jbc.M702969200</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Reed JC, Zha H, Aime-Sempe C, et al. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv Exp Med Biol. 1996;406:99-112. PMID:8910675</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Shintani-Ishida K, Yoshida K. Mitochondrial m-calpain opens the mitochondrial permeability transition pore in ischemia-reperfusion. Int J Cardiol. 2015;197:26-32. DOI:10.1016/j.ijcard.2015.06.010</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Luo T, Yue R, Hu H, et al. PD150606 protects against ischemia/reperfusion injury by preventing μ-calpain-induced mitochondrial apoptosis. Arch Biochem Biophys. 2015;586:1-9. DOI:10.1016/j.abb.2015.06.005</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Plevin MJ, Mills MM, Ikura M. The LxxLL motif: A multifunctional binding sequence in transcriptional regulation. Trends Biochem Sci. 2005;30(2):66-9. DOI:10.1016/j.tibs.2004.12.001</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Gaikwad AB, Viswanad B, Ramarao P. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. Pharmacol Res. 2007;55(5):400-7. DOI:10.1016/j.phrs.2007.01.015</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Cree MG, Newcomer BR, Herndon DN, Wolfe RR. PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial. Nutr Metab (Lond). 2007;4:9. DOI:10.1186/1743-7075-4-9</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Wu JS, Lin TN, Wu KK. Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J Cell Physiol. 2009;220(1):58-71. DOI:10.1002/jcp.21730</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Yang SH, Sharrocks AD, Whitmarsh AJ. MAP kinase signalling cascades and transcriptional regulation. Gene. 2013;513(1):1-13. DOI:10.1016/j.gene.2012.10.033</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Cook SJ, Stuart K, Gilley R, Sale MJ. Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling. FEBS J. 2017;284(24):4177-95. DOI:10.1111/febs.14122</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Nowak G, Clifton GL, Godwin ML, Bakajsova D. Activation of ERK1/2 pathway mediates oxidant-induced decreases in mitochondrial function in renal cells. Am J Physiol Renal Physiol. 2006;291(4):F840-55. DOI:10.1152/ajprenal.00219.2005</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Lu TH, Hsieh SY, Yen CC, et al. Involvement of oxidative stress-mediated ERK1/2 and p38 activation regulated mitochondria-dependent apoptotic signals in methylmercury-induced neuronal cell injury. Toxicol Lett. 2011;204(1):71-80. DOI:10.1016/j.toxlet.2011.04.013</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Liu XH, Pan LL, Gong QH, Zhu YZ. Antiapoptotic effect of novel compound from Herba leonuri – leonurine (SCM-198): A mechanism through inhibition of mitochondria dysfunction in H9c2 cells. Curr Pharm Biotechnol. 2010;11(8):895-905. DOI:10.2174/138920110793262015</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Palka G, Geraci L, Calabrese G, et al. A new case of chronic myelogenous leukemia with 14q+ marker and review of the literature. Ann Genet. 1988;31(3):190-2. PMID:3066283</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Yang JY, Yeh HY, Lin K, Wang PH. Insulin stimulates Akt translocation to mitochondria: implications on dysregulation of mitochondrial oxidative phosphorylation in diabetic myocardium. J Mol Cell Cardiol. 2009;46(6):919-26. DOI:10.1016/j.yjmcc.2009.02.015</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Kandezi N, Mohammadi M, Ghaffari M, et al. Novel insight to neuroprotective potential of curcumin: A mechanistic review of possible involvement of mitochondrial biogenesis and PI3/Akt/GSK3 or PI3/Akt/CREB/BDNF signaling pathways. Int J Mol Cell Med. 2020;9(1):1-32. DOI:10.22088/IJMCM.BUMS.9.1.1</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Sage-Schwaede A, Engelstad K, Salazar R, et al. Exploring mTOR inhibition as treatment for mitochondrial disease. Ann Clin Transl Neurol. 2019;6(9):1877-81. DOI:10.1002/acn3.50846</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>McCormack S, Polyak E, Ostrovsky J, Dingley SD. Pharmacologic targeting of sirtuin and PPAR signaling improves longevity and mitochondrial physiology in respiratory chain complex I mutant Caenorhabditis elegans. Mitochondrion. 2015;22:45-59. DOI:10.1016/j.mito.2015.02.005</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Sato M, Sato K, Tomura K, et al. The autophagy receptor ALLO-1 and the IKKE-1 kinase control clearance of paternal mitochondria in Caenorhabditis elegans. Nat Cell Biol. 2018;20(1):81-91. DOI:10.1038/s41556-017-0008-9</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Mukhopadhyay S, Das DN, Panda PK, et al. Autophagy protein Ulk1 promotes mitochondrial apoptosis through reactive oxygen species. Free Radic Biol Med. 2015;89:311-21. DOI:10.1016/j.freeradbiomed.2015.07.159</mixed-citation></ref></ref-list></back></article>
